Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?

2.

Pugh

D

,

Pugh

J

,

Mead

GE

.

Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review

.

Age Ageing

.

2011

;

40

(

6

):

675

-

683

.

doi:10.1093/ageing/afr097

.

3.

Silverstein

RL

,

Bauer

KA

,

Cushman

M

,

Esmon

CT

,

Ershler

WB

,

Tracy

RP

.

Venous thrombosis in the elderly: more questions than answers

.

Blood

.

2007

;

110

(

9

):

3097

-

3101

.

doi:10.1182/blood-2007-06-096545

.

4.

Bauersachs

R

,

Berkowitz

SD

,

Brenner

B

, et al;

EINSTEIN Investigators

.

Oral rivaroxaban for symptomatic venous thromboembolism

.

N Engl J Med

.

2010

;

363

(

26

):

2499

-

2510

.

doi:10.1056/NEJMoa1007903

.

5.

Agnelli

G

,

Buller

HR

,

Cohen

A

, et al;

AMPLIFY Investigators

.

Oral apixaban for the treatment of acute venous thromboembolism

.

N Engl J Med

.

2013

;

369

(

9

):

799

-

808

.

doi:10.1056/NEJMoa1302507

.

6.

Büller

HR

,

Décousus

H

,

Grosso

MA

, et al;

Hokusai-VTE Investigators

.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

.

N Engl J Med

.

2013

;

369

(

15

):

1406

-

1415

.

doi:10.1056/NEJMoa1306638

.

7.

Schulman

S

,

Kearon

C

,

Kakkar

AK

, et al.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

.

N Engl J Med

.

2009

;

361

(

24

):

2342

-

2352

.

doi:10.1056/nejmoa0906598

.

8.

Silverstein

MD

,

Heit

JA

,

Mohr

DN

,

Petterson

TM

,

O'Fallon

WM

,

Melton

LJ

.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

.

Arch Intern Med

.

1998

;

158

(

6

):

585

.

doi:10.1001/archinte.158.6.585

.

9.

Jaul

E

,

Barron

J.

Age-related diseases and clinical and public health implications for the 85 years old and over population

.

Front Public Health

.

2017

;

5

:

335

.

doi:10.3389/fpubh.2017.00335

.

10.

Lai

N

,

Jones

AE

,

Johnson

SA

,

Witt

DM

.

Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study

.

J Thromb Thrombolysis

.

2021

;

52

(

2

):

414

-

418

.

doi:10.1007/s11239-021-02377-8

.

11.

Ozaki

AF

,

Choi

AS

,

Le

QT

, et al.

Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis

.

Circ Cardiovasc Qual Outcomes

.

2020

;

13

(

3

):

e005969

.

doi:10.1161/CIRCOUTCOMES.119.005969

.

12.

Ferri

N

,

Colombo

E

,

Tenconi

M

,

Baldessin

L

,

Corsini

A.

Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice

.

Pharmaceutics

.

2022

;

14

(

6

).

doi:10.3390/pharmaceutics14061120

.

13.

Büller

HR

,

Prins

MH

,

Lensin

AW

, et al;

EINSTEIN–PE Investigators

.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

.

N Engl J Med

.

2012

;

366

(

14

):

1287

-

1297

.

doi:10.1056/NEJMoa1113572

.

14.

Geldhof

V

,

Vandenbriele

C

,

Verhamme

P

,

Vanassche

T.

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants

.

Thromb J

.

2014

;

12

:

21

.

doi:10.1186/1477-9560-12-21

.

15.

Masias

C

, ed.

Use of DOACs in elderly patients with acute DVT

.

International Society of Thrombosis and Hemostasis Congress

;

2023

;

Montreal

.

16.

Takahashi

K

,

Yamashita

Y

,

Morimoto

T

, et al;

COMMAND VTE Registry Investigators

.

Age and long-term outcomes of patients with venous thromboembolism: from the COMMAND VTE Registry

.

Int J Cardiol

.

2023

;

383

:

89

-

95

.

doi:10.1016/j.ijcard.2023.04.050

.

17.

Zhang

Q-L

,

Rothenbacher

D.

Prevalence of chronic kidney disease in population-based studies: systematic review

.

BMC Public Health

.

2008

;

8

:

117

.

doi:10.1186/1471-2458-8-117

.

18.

Chan

NC

,

Eikelboom

JW

.

How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism

.

Blood

.

2019

;

133

(

21

):

2269

-

2278

.

doi:10.1182/blood-2019-01-846048

.

19.

Liesenfeld

KH

,

Lehr

T

,

Dansirikul

C

, et al.

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

.

J Thromb Haemost

.

2011

;

9

(

11

):

2168

-

2175

.

doi:10.1111/j.1538-7836.2011.04498.x

.

20.

Parasrampuria

DA

,

Marbury

T

,

Matsushima

N

, et al.

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

.

Thromb Haemost

.

2015

;

113

(

4

):

719

-

727

.

doi:10.1160/TH14-06-0547

.

21.

Moore

KT

,

Wong

P

,

Zhang

L

,

Pan

G

,

Foody

JA

.

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban

.

Curr Med Res Opin

.

2018

;

34

(

12

):

2053

-

2061

.

doi:10.1080/03007995.2018.1492374

.

22.

Byon

W

,

Garonzik

S

,

Boyd

RA

,

Frost

CE

.

Apixaban: a clinical pharmacokinetic and pharmacodynamic review

.

Clin Pharmacokinet

.

2019

;

58

(

10

):

1265

-

1279

.

doi:10.1007/s40262-019-00775-z

.